Craig-Hallum bullish on Clover Health, initiates with a Buy

As previously reported, Craig-Hallum initiated coverage of Clover Health (CLOV) with a Buy rating and $6 price target The firm believes Clover Health is a disrupter in the physician enablement and Medicare Advantage markets and its Clover Assistant, which utilizes AI and ML, is changing the way patients are treated, and in turn is reducing cost of care and ultimately leading to greater cash flow and earnings to shareholders.